Abstract
β-Amino acids are being increasingly used in the design of bioactive ligands and more recently in the generation of novel biomaterials. Peptides containing either individual β-amino acid substitutions or peptides comprised entirely of β-amino acids, display unique properties in terms of their structural and/or chemical characteristics. β-Peptides form well-defined secondary structures that exhibit different geometries compared to the corresponding α-peptides. β-Peptides, including α-peptides containing only one or two β-amino acids, can be easily modified with different functional groups and are metabolically stable and, together with the predictable side chain topography, have led to the design of a growing number of bioactive β-peptides with a range of biological targets and therapeutic applications. More recently, our understanding of the folding and self-assembly of β-peptides has resulted in the generation of novel biomaterials. The focus of this review is to examine how the structural and chemical properties of β-peptides have been exploited in the design of bioactive peptides and selfassembled nanomaterials.
Keywords: β-Peptides, β-amino acids, peptidomimetic, bioactive ligand, proteolytic stability, self-assembly, biomaterials.
Current Pharmaceutical Design
Title:Using β-Amino Acids and β-Peptide Templates to Create Bioactive Ligands and Biomaterials
Volume: 23 Issue: 26
Author(s): Mark P Del Borgo, Ketav Kulkarni and Marie-Isabel Aguilar*
Affiliation:
- Biomedicine Discovery Institute & Department of Biochemistry and Molecular Biology, Monash University, Wellington Rd, Clayton, Vic. 3800,Australia
Keywords: β-Peptides, β-amino acids, peptidomimetic, bioactive ligand, proteolytic stability, self-assembly, biomaterials.
Abstract: β-Amino acids are being increasingly used in the design of bioactive ligands and more recently in the generation of novel biomaterials. Peptides containing either individual β-amino acid substitutions or peptides comprised entirely of β-amino acids, display unique properties in terms of their structural and/or chemical characteristics. β-Peptides form well-defined secondary structures that exhibit different geometries compared to the corresponding α-peptides. β-Peptides, including α-peptides containing only one or two β-amino acids, can be easily modified with different functional groups and are metabolically stable and, together with the predictable side chain topography, have led to the design of a growing number of bioactive β-peptides with a range of biological targets and therapeutic applications. More recently, our understanding of the folding and self-assembly of β-peptides has resulted in the generation of novel biomaterials. The focus of this review is to examine how the structural and chemical properties of β-peptides have been exploited in the design of bioactive peptides and selfassembled nanomaterials.
Export Options
About this article
Cite this article as:
Del Borgo P Mark, Kulkarni Ketav and Aguilar Marie-Isabel *, Using β-Amino Acids and β-Peptide Templates to Create Bioactive Ligands and Biomaterials, Current Pharmaceutical Design 2017; 23 (26) . https://dx.doi.org/10.2174/1381612823666170616083031
DOI https://dx.doi.org/10.2174/1381612823666170616083031 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Physical Disability in Older Adults
Current Aging Science QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Diabetes-induced Proteome Changes Throughout Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Noradrenaline-mediated Inhibition of Inflammatory Cytokines is Altered in Macrophages from Obese Zucker Rats: Effect of Habitual Exercise
Endocrine, Metabolic & Immune Disorders - Drug Targets Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets The Relaxin Peptide Family – Structure, Function and Clinical Applications
Protein & Peptide Letters Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology Editorial: Preeclampsia-Eclampsia, Time to Act and Time to Deepen Research
Current Women`s Health Reviews Editorial [ Murine Atherosclerosis (Part III) Guest Editor: Godfrey S. Getz ]
Current Drug Targets Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension
Current Drug Metabolism Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Diltiazem Analogues: The Last Ten Years on Structure Activity Relationships
Current Medicinal Chemistry Atherosclerotic Coronary Heart Disease Epidemiology, Classification and Management
Cardiovascular & Hematological Disorders-Drug Targets Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Current Cancer Drug Targets